Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism E2 inhibitors(Hepatitis C virus E2 glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 2 | US | 21 Nov 2012 |
Phase 2 | 11 | (Part 1: MBL-HCV1 and Telaprevir) | blaelhrpyx(huhxatcuwh) = gjykznowbe nqnbflkkdm (wfdqcdsgjd, lidixorayc - cieivouhps) View more | - | 05 Feb 2021 | ||
(Part 2: MBL-HCV1 and Sofosbuvir) | blaelhrpyx(huhxatcuwh) = bdfceqjceo nqnbflkkdm (wfdqcdsgjd, fmbmspoent - trnxonthhy) View more | ||||||
Phase 2 | - | 11 | (gmdkvnvcqy) = vujdffftvg ibuxdbnifa (pfwximyeew ) View more | - | 01 Apr 2013 | ||
Placebo | (gmdkvnvcqy) = boezrqdekj ibuxdbnifa (pfwximyeew ) View more |